Matthew L. Kaplan
CIK: 0001895952
Transaction Breakdown
Open Market Buys (P)1 (33.3%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NVCT
Nuvectis Pharma, Inc.
Director
Discretionary Trading P&L
Holdings
About Kaplan Matthew L.
Kaplan Matthew L. (SEC CIK 0001895952) files insider reports with the SEC as Director of Nuvectis Pharma, Inc. (NVCT).
Signal8 holds 3 ownership filings by Kaplan Matthew L., all Form 4s, filed between Jun 12, 2025 and Jun 12, 2026. Those filings report 3 transactions, from Jun 12, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kaplan Matthew L.'s filings is in FORT LEE, NJ.
Recent filings by Kaplan Matthew L.
Other insiders filing for Nuvectis Pharma, Inc. (NVCT)
- Carson Michael J., Vice President, Finance
- Mosseri Marlio Charles, 10% Owner
- BENTSUR RON, Chairman & CEO
- Hoberman Kenneth, Director
- Oliviero James F III, Director
- Sanchez Juan, Director